By Doug Macron

Although Alnylam Pharmaceuticals and the Max Planck Institute contend in a lawsuit that the US Patent and Trademark Office is poised to issue a patent from the Tuschl-I intellectual property portfolio, the defendants in the case argued this week that this expectation is mere speculation.

For this and other reasons, the defendants told the court, Alnylam and Max Planck's request for a court order essentially blocking any kind of Tuschl-I patent issuance is unnecessary and potentially damaging.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.